论文部分内容阅读
目的研究舒利迭结合孟鲁斯特钠药物在治疗咳嗽变异性哮喘疾病过程中的疗效。方法选取我院2015年1月~2016年1月收治的咳嗽变异性哮喘患者110例,将其随机分为治疗组和对照组,各55例,对照组欲将使用舒利迭药,治疗组使用舒利迭与孟鲁斯特钠结合,记录患者服药后的病发情况,咳嗽的次数,以及症状消失时间,对各组治疗后的疗效进行分析,并得出实验结论。结果对照组对咳嗽变异性哮喘的治疗有效率为70.1%,而治疗组为92.7%,与对照组治疗疗效相比,治疗组的疗效显著增加;差异有统计学意义(P<0.05)。结论与使用舒利迭单味药相比,舒利迭与孟鲁斯特钠联用治疗咳嗽变异性哮喘疗效更加显著,在临床治疗方法中具有很大的实践价值,值得推广。
Objective To study the efficacy of seretide combined with sodium montelukast in the treatment of cough variant asthma. Methods One hundred and ten patients with cough variant asthma admitted in our hospital from January 2015 to January 2016 were randomly divided into treatment group and control group, with 55 cases in each group. Patients in control group were enrolled in treatment group The use of Seretide and sodium combined with montelukast, record the patient after taking the disease, the number of coughs, and the disappearance of symptoms, the efficacy of each group after treatment analysis and draw experimental conclusions. Results The effective rate of treatment of cough variant asthma in control group was 70.1%, while that in treatment group was 92.7%. The curative effect of treatment group was significantly higher than that of control group. The difference was statistically significant (P <0.05). Conclusion Compared with the single drug seretide, seretide combined with montelukast sodium in the treatment of cough variant asthma is more significant effect, in the clinical treatment has great practical value, it is worth promoting.